ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company’s lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA will be re-submitted in the U.S. by April 2012. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International. These include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer in partnership with Roche.

Leuven, BE
Size (employees)
80 (est)-8%
ThromboGenics is headquartered in Leuven, BE
Report incorrect company information

Key People/Management at ThromboGenics

Patrik de Haes

Patrik de Haes

Chief Executive Officer
Dominique Vanfleteren

Dominique Vanfleteren

Chief Financial Officer

ThromboGenics Office Locations

ThromboGenics has an office in Leuven
Leuven, BE (HQ)
1 Gaston Geenslaan
Show all (1)
Report incorrect company information

ThromboGenics Financials and Metrics

ThromboGenics Financials

Market capitalization (31-Oct-2017)

161.4 m

Closing share price (31-Oct-2017)

ThromboGenics's current market capitalization is €161.4 m.
Show all financial metrics
Report incorrect company information